Sorrento Therapeutics, Inc. Stock
Stocks
SRNE
US83587F2020
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.001000 USD | 0.00% |
|
+42.86% | -61.54% |
| 03-17 | Semnur Pharmaceuticals, Inc. Announces CEO Changes, Effective March 13, 2026 | CI |
| 03-17 | Semnur Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 67.15M 58.68M 54.15M 49.91M 94.08M 6.47B 96.16M 647M 255M 3.17B 252M 247M 10.9B | P/E 2021 |
-3.2x | P/E 2022 | -0.65x |
|---|---|---|---|---|---|
| Enterprise Value | 152M 133M 122M 113M 212M 14.61B 217M 1.46B 575M 7.15B 570M 557M 24.63B | EV / Sales 2021 |
29.1x | EV / Sales 2022 | 7.89x |
| Free-Float |
98.65% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 week | +42.86% | ||
| Current month | +66.67% | ||
| 1 month | -9.09% | ||
| 3 months | +25.00% | ||
| 6 months | -71.43% | ||
| Current year | -61.54% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0 |
| Current year | 0 | | 0.01 |
| 1 year | 0 | | 0.1 |
| 3 years | 0 | | 0.4 |
| 5 years | 0 | | 9.63 |
| 10 years | 0 | | 19.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 61 | 2011-03-31 |
Scott Schaus
CTO | Chief Tech/Sci/R&D Officer | - | 2022-02-28 |
John Waldheim
LAW | General Counsel | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Henry Ji
CHM | Chairman | 61 | 2017-07-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +42.86% | -28.57% | -99.75% | 544K | |
| +0.24% | -1.54% | +52.85% | +60.31% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.70% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +413.12% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -16.17% | 23.13B | |
| +3.79% | +3.05% | +37.36% | -4.92% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -31.21% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +291.24% | 15.2B | |
| +5.88% | +2.38% | +36.65% | +661.62% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +186.18% | 14.06B | |
| Average | -0.20% | +1.92% | +35.56% | +153.41% | 23.36B | |
| Weighted average by Cap. | -1.15% | -2.36% | +40.93% | +139.69% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 52.9M 46.23M 42.66M 39.32M 74.12M 5.09B 75.76M 510M 201M 2.5B 199M 194M 8.59B | 62.84M 54.92M 50.67M 46.71M 88.04M 6.05B 89.99M 606M 238M 2.96B 236M 231M 10.2B |
| Net income | -428M -374M -345M -318M -600M -41.25B -613M -4.13B -1.62B -20.2B -1.61B -1.57B -69.54B | -573M -501M -462M -426M -803M -55.17B -820M -5.52B -2.17B -27.02B -2.15B -2.1B -93.01B |
| Net Debt | 111M 96.74M 89.27M 82.28M 155M 10.66B 159M 1.07B 420M 5.22B 416M 407M 17.97B | 84.53M 73.87M 68.16M 62.83M 118M 8.14B 121M 815M 320M 3.99B 317M 310M 13.72B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-17 | US$0.001000 | 0.00% | 651,724 |
| 26-07-16 | US$0.001000 | +66.67% | 163,439 |
| 26-07-15 | US$0.000600 | 0.00% | 24,795 |
| 26-07-14 | US$0.000600 | -14.29% | 5,743 |
| 26-07-13 | US$0.000700 | 0.00% | 345,072 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SRNE Stock
Select your edition
All financial news and data tailored to specific country editions
